Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 2
1974 7
1975 3
1976 2
1977 3
1978 5
1979 5
1980 7
1981 7
1982 8
1983 5
1984 4
1985 7
1986 9
1987 2
1988 4
1989 6
1990 9
1991 8
1992 9
1993 9
1994 11
1995 10
1996 12
1997 13
1998 8
1999 3
2000 4
2001 7
2002 4
2003 5
2004 4
2005 7
2006 6
2007 8
2008 4
2009 6
2010 7
2011 10
2012 7
2013 9
2014 12
2015 5
2016 8
2017 9
2018 11
2019 5
2020 4
2021 5
2022 6
2023 4
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

320 results

Results by year

Filters applied: . Clear all
Page 1
Targeting the MAPK Pathway in KRAS-Driven Tumors.
Drosten M, Barbacid M. Drosten M, et al. Cancer Cell. 2020 Apr 13;37(4):543-550. doi: 10.1016/j.ccell.2020.03.013. Cancer Cell. 2020. PMID: 32289276 Free article. Review.
Rapid adaptation to CDK2 inhibition exposes intrinsic cell-cycle plasticity.
Arora M, Moser J, Hoffman TE, Watts LP, Min M, Musteanu M, Rong Y, Ill CR, Nangia V, Schneider J, Sanclemente M, Lapek J, Nguyen L, Niessen S, Dann S, VanArsdale T, Barbacid M, Miller N, Spencer SL. Arora M, et al. Cell. 2023 Jun 8;186(12):2628-2643.e21. doi: 10.1016/j.cell.2023.05.013. Epub 2023 Jun 1. Cell. 2023. PMID: 37267950
Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS.
Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T, Michels J, Baumert H, Miles L, Campbell NM, de Stanchina E, Solit DB, Barbacid M, Taylor BS, Rosen N. Yao Z, et al. Nature. 2017 Aug 10;548(7666):234-238. doi: 10.1038/nature23291. Epub 2017 Aug 2. Nature. 2017. PMID: 28783719 Free PMC article.
Kras oncogene ablation prevents resistance in advanced lung adenocarcinomas.
Salmón M, Álvarez-Díaz R, Fustero-Torre C, Brehey O, Lechuga CG, Sanclemente M, Fernández-García F, López-García A, Martín-Guijarro MC, Rodríguez-Perales S, Bousquet-Mur E, Morales-Cacho L, Mulero F, Al-Shahrour F, Martínez L, Domínguez O, Caleiras E, Ortega S, Guerra C, Musteanu M, Drosten M, Barbacid M. Salmón M, et al. J Clin Invest. 2023 Apr 3;133(7):e164413. doi: 10.1172/JCI164413. J Clin Invest. 2023. PMID: 36928090 Free PMC article.
Structure of the RAF1-HSP90-CDC37 complex reveals the basis of RAF1 regulation.
García-Alonso S, Mesa P, Ovejero LP, Aizpurua G, Lechuga CG, Zarzuela E, Santiveri CM, Sanclemente M, Muñoz J, Musteanu M, Campos-Olivas R, Martínez-Torrecuadrada J, Barbacid M, Montoya G. García-Alonso S, et al. Mol Cell. 2022 Sep 15;82(18):3438-3452.e8. doi: 10.1016/j.molcel.2022.08.012. Epub 2022 Sep 1. Mol Cell. 2022. PMID: 36055235 Free article.
KRAS inhibitors: going noncovalent.
Drosten M, Barbacid M. Drosten M, et al. Mol Oncol. 2022 Dec;16(22):3911-3915. doi: 10.1002/1878-0261.13341. Epub 2022 Nov 27. Mol Oncol. 2022. PMID: 36383067 Free PMC article.
Returning home.
Barbacid M. Barbacid M. Cell. 2007 May 18;129(4):641-4. doi: 10.1016/j.cell.2007.05.010. Cell. 2007. PMID: 17512394 Free article.
320 results